138 related articles for article (PubMed ID: 17692744)
1. Effects of multiple oral doses of an A1 adenosine antagonist, BG9928, in patients with heart failure: results of a placebo-controlled, dose-escalation study.
Greenberg B; Thomas I; Banish D; Goldman S; Havranek E; Massie BM; Zhu Y; Ticho B; Abraham WT
J Am Coll Cardiol; 2007 Aug; 50(7):600-6. PubMed ID: 17692744
[TBL] [Abstract][Full Text] [Related]
2. Effects of BG9928, an adenosine A₁ receptor antagonist, in patients with congestive heart failure.
Gottlieb SS; Ticho B; Deykin A; Abraham WT; Denofrio D; Russell SD; Chapman D; Smith W; Goldman S; Thomas I
J Clin Pharmacol; 2011 Jun; 51(6):899-907. PubMed ID: 20926754
[TBL] [Abstract][Full Text] [Related]
3. The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment.
Dittrich HC; Gupta DK; Hack TC; Dowling T; Callahan J; Thomson S
J Card Fail; 2007 Oct; 13(8):609-17. PubMed ID: 17923351
[TBL] [Abstract][Full Text] [Related]
4. Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure.
Mitrovic V; Seferovic P; Dodic S; Krotin M; Neskovic A; Dickstein K; de Voogd H; Böcker C; Ziegler D; Godes M; Nakov R; Essers H; Verboom C; Hocher B
Circ Heart Fail; 2009 Nov; 2(6):523-31. PubMed ID: 19919976
[TBL] [Abstract][Full Text] [Related]
5. The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance.
Givertz MM; Massie BM; Fields TK; Pearson LL; Dittrich HC;
J Am Coll Cardiol; 2007 Oct; 50(16):1551-60. PubMed ID: 17936154
[TBL] [Abstract][Full Text] [Related]
6. The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment.
Cotter G; Dittrich HC; Weatherley BD; Bloomfield DM; O'Connor CM; Metra M; Massie BM;
J Card Fail; 2008 Oct; 14(8):631-40. PubMed ID: 18926433
[TBL] [Abstract][Full Text] [Related]
7. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction.
Udelson JE; McGrew FA; Flores E; Ibrahim H; Katz S; Koshkarian G; O'Brien T; Kronenberg MW; Zimmer C; Orlandi C; Konstam MA
J Am Coll Cardiol; 2007 Jun; 49(22):2151-9. PubMed ID: 17543634
[TBL] [Abstract][Full Text] [Related]
8. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure.
Massie BM; O'Connor CM; Metra M; Ponikowski P; Teerlink JR; Cotter G; Weatherley BD; Cleland JG; Givertz MM; Voors A; DeLucca P; Mansoor GA; Salerno CM; Bloomfield DM; Dittrich HC;
N Engl J Med; 2010 Oct; 363(15):1419-28. PubMed ID: 20925544
[TBL] [Abstract][Full Text] [Related]
9. Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function.
Weatherley BD; Cotter G; Dittrich HC; DeLucca P; Mansoor GA; Bloomfield DM; Ponikowski P; O'Connor CM; Metra M; Massie BM;
J Card Fail; 2010 Jan; 16(1):25-35. PubMed ID: 20123315
[TBL] [Abstract][Full Text] [Related]
10. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine.
Wang DJ; Dowling TC; Meadows D; Ayala T; Marshall J; Minshall S; Greenberg N; Thattassery E; Fisher ML; Rao K; Gottlieb SS
Circulation; 2004 Sep; 110(12):1620-5. PubMed ID: 15337695
[TBL] [Abstract][Full Text] [Related]
11. A single supratherapeutic dose of rolofylline does not prolong the QTcF interval in healthy volunteers.
Radziszewski W; Lai E; Lazarus Shipitofsky N; Stroh M; Dishy V; Han L; Lewis W; Johnson-Levonas AO; Lutz R; Wagner J
Am J Ther; 2010; 17(1):8-16. PubMed ID: 20027105
[TBL] [Abstract][Full Text] [Related]
12. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.
Gheorghiade M; Niazi I; Ouyang J; Czerwiec F; Kambayashi J; Zampino M; Orlandi C;
Circulation; 2003 Jun; 107(21):2690-6. PubMed ID: 12742979
[TBL] [Abstract][Full Text] [Related]
13. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial.
Udelson JE; Orlandi C; Ouyang J; Krasa H; Zimmer CA; Frivold G; Haught WH; Meymandi S; Macarie C; Raef D; Wedge P; Konstam MA; Gheorghiade M
J Am Coll Cardiol; 2008 Nov; 52(19):1540-5. PubMed ID: 19007589
[TBL] [Abstract][Full Text] [Related]
14. Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial.
Blair JE; Macarie C; Ruzyllo W; Bacchieri A; Valentini G; Bianchetti M; Pang PS; Harinstein ME; Sabbah HN; Filippatos GS; Gheorghiade M;
Am J Ther; 2008; 15(3):231-40. PubMed ID: 18496261
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
[TBL] [Abstract][Full Text] [Related]
16. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients.
Abraham WT; Shamshirsaz AA; McFann K; Oren RM; Schrier RW
J Am Coll Cardiol; 2006 Apr; 47(8):1615-21. PubMed ID: 16630999
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study.
Kahan BD; Karlix JL; Ferguson RM; Leichtman AB; Mulgaonkar S; Gonwa TA; Skerjanec A; Schmouder RL; Chodoff L
Transplantation; 2003 Oct; 76(7):1079-84. PubMed ID: 14557756
[TBL] [Abstract][Full Text] [Related]
18. Protective effect of tonapofylline (BG9928), an adenosine A1 receptor antagonist, against cisplatin-induced acute kidney injury in rats.
Gill A; Wortham K; Costa D; Davis W; Ticho B; Whalley E
Am J Nephrol; 2009; 30(6):521-6. PubMed ID: 19828940
[TBL] [Abstract][Full Text] [Related]
19. Functional role of endogenous adenosine in human chronic renal disease.
Balakrishnan VS; Coles GA; Williams JD
Exp Nephrol; 1996; 4(1):26-36. PubMed ID: 8788597
[TBL] [Abstract][Full Text] [Related]
20. Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: results of the oral enoximone in intravenous inotrope-dependent subjects trial.
Feldman AM; Oren RM; Abraham WT; Boehmer JP; Carson PE; Eichhorn E; Gilbert EM; Kao A; Leier CV; Lowes BD; Mathier MA; McGrew FA; Metra M; Zisman LS; Shakar SF; Krueger SK; Robertson AD; White BG; Gerber MJ; Wold GE; Bristow MR;
Am Heart J; 2007 Nov; 154(5):861-9. PubMed ID: 17967591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
